Palisade Bio (NASDAQ:PALI) Announces Earnings Results, Beats Estimates By $0.02 EPS

Palisade Bio (NASDAQ:PALIGet Rating) posted its quarterly earnings results on Friday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02, MarketWatch Earnings reports.

NASDAQ PALI traded up $0.03 during trading on Friday, hitting $0.51. 172,732 shares of the company’s stock were exchanged, compared to its average volume of 359,028. The company has a market cap of $9.22 million, a PE ratio of -0.16 and a beta of 1.63. The stock’s 50 day moving average price is $0.88 and its two-hundred day moving average price is $1.38. Palisade Bio has a fifty-two week low of $0.40 and a fifty-two week high of $4.57.

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in shares of Palisade Bio during the second quarter worth about $42,000. Northern Trust Corp bought a new stake in shares of Palisade Bio during the fourth quarter worth about $30,000. Renaissance Technologies LLC bought a new stake in shares of Palisade Bio during the fourth quarter worth about $105,000. Geode Capital Management LLC grew its holdings in shares of Palisade Bio by 595.2% during the third quarter. Geode Capital Management LLC now owns 171,530 shares of the company’s stock worth $454,000 after purchasing an additional 146,855 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Palisade Bio by 11.5% during the first quarter. Vanguard Group Inc. now owns 271,604 shares of the company’s stock worth $288,000 after purchasing an additional 28,014 shares during the last quarter. Institutional investors own 7.88% of the company’s stock.

Several research analysts have commented on PALI shares. Zacks Investment Research raised Palisade Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. LADENBURG THALM/SH SH started coverage on Palisade Bio in a research note on Wednesday, February 2nd. They set a “buy” rating and a $5.00 target price for the company.

Palisade Bio Company Profile (Get Rating)

Palisade Bio, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery.

Featured Articles

Earnings History for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.